Latest Quest Diagnostics Stories
Largest study of LDL blood levels, based on tests of nearly 105 million Americans, suggests improvements in cardiovascular health may have stalled in recent years MADISON, N.J., May 13, 2013 /PRNewswire/ -- Decades of declines in LDL cholesterol blood levels, a key marker of death risk from heart disease, abruptly ended in 2008, and may have stalled since, according to a multi-year, national study published in PLOS ONE. The study, by researchers at Quest Diagnostics (NYSE: DGX),...
Transaction expected to deliver innovative and high-quality diagnostic information services at lower costs to patients MADISON, N.J. and SAN FRANCISCO, April 17, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has entered into a definitive agreement to acquire lab-related clinical outreach service operations of Dignity Health, a hospital system based in California. Under the agreement,...
MADISON, N.J., April 9, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed the sale of its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances. HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide. In February 2013,...
Based on 14-3-3eta protein biomarker for aiding early RA diagnosis through an exclusive license with Augurex Life Sciences MADISON, N.J., April 9, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of two new blood tests for aiding the early diagnosis of rheumatoid arthritis (RA), an autoimmune disorder that can cause debilitating joint damage. The lab-developed tests are based on the...
Quest Diagnostics Health Trends(TM) analysis also finds marijuana is the most commonly abused drug in the United States, but medical marijuana users are not more likely to misuse other drugs MADISON, N.J., April 8, 2013 /PRNewswire/ -- Individuals who use marijuana recreationally are more likely to misuse other drugs, including pain-controlling, but potentially addictive narcotics, sedatives and other prescription medications, than individuals who do not use marijuana, according to...
MADISON, N.J., April 5, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2013 results on Wednesday, April 17, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests...
Quest Diagnostics Health Trends(TM) analysis of a quarter million test results finds three out of five Americans tested misused their prescription medications, including through potentially dangerous drug combinations MADISON, N.J., April 3, 2013 /PRNewswire/ -- Despite increased public attention on the epidemic of prescription medication abuse, about three in five Americans tested misused their prescription drugs in 2012, virtually the same as in 2011, according to a national study...
MADISON, N.J., April 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that Sukumar Nagendran, M.D., has joined Quest Diagnostics as vice president, medical affairs, a new position. In this role, Dr. Nagendran will provide medical oversight for the company's diagnostic information services. He reports to Jon R. Cohen, M.D., senior vice president and chief medical officer, and will be based at the...
U.S. Department of Health and Human Services issues medical guidelines recommending genotypic testing to aid HIV therapy selection MADISON, N.J., March 27, 2013 /PRNewswire/ -- A new test based on gene sequencing may be used to assess a patient's suitability for treatment with CCR5 antagonists, a class of HIV antiretroviral therapies, under new medical guidelines issued by the U.S. Department of Health and Human Services (DHHS). The new genotypic test performs comparably to the...
Quest Diagnostics to use PrimeraDx's ICEPlex® platform for the development of multiplexed, multi-modal diagnostic information services MANSFIELD, Mass., March 26, 2013 /PRNewswire/ -- PrimeraDx, Inc., a molecular diagnostics company, today announced it has formed a non-exclusive diagnostics co-development agreement with Quest Diagnostics (NYSE: DGX), the world's leading diagnostics information services company. The intent of the collaboration is to co-develop and commercialize...
